innovation in heart and vascular science
From Myosin Inhibitors to Sarcomere Modulators: The Next Era in HCM Care
Dr Owens also shares insights from recent clinical trial data highlighting emerging sarcomere-targeted therapies, including aficamten and the investigational agent EDG-7500. The conversation examines how these novel approaches may reshape treatment paradigms, improve functional capacity and address longstanding therapeutic gaps for patients with non-obstructive HCM, while offering a preview of where the field may be headed next.
Listen →